Nerviano, Italy and Suresnes, France:
Nerviano Medical Sciences, the largest pharmaceutical R&D facility in
Italy, one of the leading oncology-focused, integrated discovery and
development companies in Europe, and Servier, a leading research-based
European pharmaceutical company today announced a collaboration and
worldwide license agreement to further develop and commercialize
first-in-class Nerviano compounds inhibiting the protein kinase
TTK/MPS1. A key regulator of mitosis TTK/MPS1 is aberrantly
overexpressed in a wide range of tumours and represents a promising
target in oncology.
Terms of the collaboration include an upfront fee of € 8 million and a
potential for up to € 100 million in option fees, clinical and
regulatory milestones in addition to royalties for the sale of licensed
Under the terms of the agreement, Nerviano will complete the preclinical
development of the lead candidate drug and, if Servier exercises the
option, Servier will bear all development and commercialization costs.
Nerviano will continue to support Servier for the early clinical
development and the supply of the licensed product.
“We are very pleased to enter into this partnership with Servier, as
both companies share the common goal to develop innovative drugs in
oncology”, said Prof. Alberto Scium, President of Nerviano Medical
Sciences. “I am confident that Nerviano’s expertise in drug discovery
and development will lead to new therapies that will ultimately deliver
hope and innovative therapies to cancer patients.”
“This agreement between Servier and Nerviano Medical Sciences for
developing a “first-in-class” anticancer treatment is in line with
Servier's main objective to provide patients and doctors with innovative
therapeutic solutions for severe diseases such as cancer” said
Jean-Philippe Seta, MD, CEO of Servier.
“We have preclinical data which suggest that TTK may represent an
attractive therapeutic target in a poor prognosis associated subgroup of
breast cancer. Nerviano has a strong expertise in oncology research.
Combining our capabilities will accelerate the translation of our
findings into the clinic”, said Stphane Depil, M.D., Ph.D., director of
Oncology R&D at Servier.
About Nerviano Medical Sciences (www.nervianoms.com)Nerviano
Medical Sciences (NMS) is a research based company dedicated to the
discovery and development of breakthrough treatments for cancer.NMS
has already in place collaborations or licenses with other major
pharmaceutical companies such as Genentech/Roche, Pfizer and Novartis as
well as with biotechnology companies and academia.Since December
31, 2011 NMS is indirectly owned by Regione Lombardia through the
Regional Foundation for Biomedical Research (FRRB).
About Servier (www.servier.com)Servier
is a privately-run research based pharmaceutical company with a 2012
turnover of €3.9 billion. Servier reinvests 25% of its turnover in
Research & Development in oncology, cardiovascular, metabolic,
neurological, psychiatric and rheumatological diseases.
is established in 140 countries worldwide with over 20,000 employees.
NMS / Barabino & Partners: Tel. +39 02.72.02.35.35
Stefania Bassi, Mob. +39 3220.127.116.117
Marco Catalani, Mob. +39 318.104.22.1681
Servier Communication Department
Tel: +33 1 55 72 60 37